Daily Cardiology Research Analysis
Among 80 cardiology-related papers screened, three stood out for immediate clinical and translational impact: a nationwide difference-in-differences study showing that switching to high-sensitivity troponin assays reduces costs and 12‑month MACE (especially in women), a very large prospective cohort linking higher cardiorespiratory fitness to lower mortality in CKD, and a dual-cohort validation demonstrating angiography-derived IMR can noninvasively identify ischemia in ANOCA. Together, they adv
Summary
Among 80 cardiology-related papers screened, three stood out for immediate clinical and translational impact: a nationwide difference-in-differences study showing that switching to high-sensitivity troponin assays reduces costs and 12‑month MACE (especially in women), a very large prospective cohort linking higher cardiorespiratory fitness to lower mortality in CKD, and a dual-cohort validation demonstrating angiography-derived IMR can noninvasively identify ischemia in ANOCA. Together, they advance diagnosis, prevention, and value-based care.
Research Themes
- Value-based diagnostics: high-sensitivity troponin adoption and outcomes
- Exercise capacity as a prognostic 'vital sign' in CKD
- Noninvasive microvascular assessment in ANOCA (angio-IMR)
Selected Articles
1. Cost-effectiveness of the transition from conventional to high-sensitivity troponin assay for the investigation and management of suspected acute coronary syndrome in the emergency department.
In a difference-in-differences analysis of 179,681 suspected ACS ED presentations across 9 Australian tertiary hospitals, switching to hs-cTn reduced index episode costs by $1,022, 12‑month total costs by $1,373, and 12‑month MACE by 0.55%, with greater reductions among women (−1.17%). These data support system-wide adoption of hs-cTn with sex-specific thresholds.
Impact: Provides robust real-world economic and clinical evidence that hs-cTn adoption improves outcomes and lowers costs, with sex-specific benefits.
Clinical Implications: Health systems should adopt hs-cTn with sex-specific thresholds in ED pathways for suspected ACS to reduce MACE and costs, ensuring protocols and staffing support rapid rule-out/rule-in algorithms.
Key Findings
- Difference-in-differences across 179,681 ED encounters showed index event cost reduction of $1,022 (95% CI −$1,034 to −$1,009) after hs-cTn adoption.
- Total 12-month costs decreased by $1,373 (95% CI −$1,387 to −$1,360) with hs-cTn implementation.
- 12-month MACE decreased by 0.55% overall, with a larger absolute reduction in women (−1.17%).
Methodological Strengths
- Large multicenter quasi-experimental design (difference-in-differences) minimizing confounding by temporal trends.
- Linked administrative data enabling comprehensive cost and outcome capture over 12 months.
Limitations
- Nonrandomized observational design may retain residual confounding.
- Conducted in Australian tertiary hospitals, which may limit generalizability to other health systems.
Future Directions: Assess implementation fidelity and equity impacts (e.g., sex- and age-specific algorithms), and evaluate downstream testing and admissions to optimize pathway design.
BACKGROUND: Switching from conventional to high-sensitivity cardiac troponin (hs-cTn) assays with sex-specific reference rates for threshold troponin levels enables detection of smaller amounts of myocardial damage. However, the real-world impact of these assays on patient outcomes and health service costs is poorly understood. We investigated the cost-effectiveness of switching to hs-cTn assays for patients presenting to Australian Emergency Departments (EDs) with suspected acute coronary syndrome (ACS) with a 12-month follow-up period. METHODS: Using linked administrative data from 9 tertiary hospitals for patients aged 20 and above who presented to ED with suspected ACS between March 2011 and November 2015, we applied a difference-in-differences methodology to compare costs and major adverse cardiac events between hospitals switching to hs-cTn assays and hospitals continuing to use conventional assays. RESULTS: We identified 179,681 consecutive patients, of whom 87,019 presented during the preperiod and 92,662 the postperiod. Switching to hs-cTn was associated with a reduction in the cost of the index event (-$1,022, 95% CI: -$1,034, -$1,009), a reduction in total costs at 12 months (-$1,373, 95% CI: -$1,387, -$1,360) and a reduction in the percentage of patients experiencing a MACE outcome within 12-months (-0.55%, 95% CI: -0.88%, -0.21%). The reduction in MACE outcomes was larger for female patients (-1.17%, 95% CI: -1.19%, -1.14%) than for all patients and for males. CONCLUSIONS: The switch to hs-cTn is highly cost-effective across all patients and for each sex. The reduction in MACE outcomes and costs within 12 months are greater for females than for males.
2. Cardiorespiratory Fitness and Mortality in Patients With Chronic Kidney Disease: A Prospective Cohort Study.
Among 45,674 CKD patients undergoing treadmill testing, each 1‑MET increase in CRF was associated with a 12% lower mortality risk over 15.9 years, with graded benefits across fitness categories and consistent effects across age, race, and sex. Findings position CRF as a modifiable prognostic marker in CKD.
Impact: Defines CRF as a strong, graded, and independent predictor of mortality in CKD using objective fitness testing and long-term follow-up.
Clinical Implications: Incorporate exercise assessment and prescription into CKD care; consider CRF as a ‘vital sign’ for risk stratification and target for intervention (e.g., supervised exercise, cardiac rehabilitation-style programs).
Key Findings
- Over 15.9 years, 53.2% died; each 1-MET higher CRF associated with 12% lower mortality (HR 0.88; 95% CI 0.875–0.885).
- Compared with least-fit, adjusted HRs were 0.76, 0.63, 0.49, and 0.33 for low, moderate, fit, and high fitness, respectively.
- Associations were consistent across age, race, and sex strata.
Methodological Strengths
- Very large, multiethnic cohort with objective treadmill-based CRF measurement.
- Long follow-up (median 15.9 years) with graded risk assessment across predefined fitness categories.
Limitations
- Observational design precludes causal inference despite extensive adjustment.
- Predominantly veteran population may limit generalizability (e.g., sex distribution).
Future Directions: Randomized trials testing exercise interventions to raise CRF in CKD; integration of CRF into CKD risk calculators and referral pathways to exercise programs.
OBJECTIVE: To assess the association between objectively measured cardiorespiratory fitness (CRF) and mortality in patients with chronic kidney disease (CKD). PATIENTS AND METHODS: From a large cohort of US veterans (n=750,302) based on the ETHOS (Exercise Testing and Health Outcomes) study, we identified 45,674 men and women aged 30 to 95 years (mean, 65.1 ± 8.8 years) who completed an exercise treadmill test (ETT) within the Veterans Affairs hospitals across the United States. All were diagnosed with CKD before the ETT by International Classification of Diseases 9 RESULTS: During 15.9 years of follow-up, 24,310 individuals (53.2%) died. The adjusted association between CRF and mortality risk was inverse and graded. For each 1-MET increase in CRF, the adjusted HR for mortality was 12% lower (HR, 0.88; 95% CI, 0.875 to 0.885; P<.001). When risk was assessed across CRF categories using the least-fit CRF category as the referent, the adjusted HRs and CIs were 0.76 (95% CI, 0.73 to 0.78), 0.63 (95% CI, 0.61 to 0.66), 0.49 (95% CI, 0.47 to 0.51), and 0.33 (95% CI, 0.30 to 0.35), for low-fit, moderate-fit, fit, and high-fit individuals, respectively. The pattern of the CRF mortality risk association was similar regardless of age, race, or sex. CONCLUSION: In this large multiethnic study, we found an independent, inverse, and graded association between CRF and mortality in CKD patients. These findings underscore the importance of increasing CRF in CKD patients to lower the risk of mortality.
3. The performance of angiography-derived index of microcirculatory resistance for ischemia in angina with non-obstructive coronary artery disease: Validated by wire-based IMR and SPECT-MPI.
Across two validation cohorts, angio-IMR≥25 showed excellent agreement with wire-based IMR≥25 (AUC 0.917; CA 91.9%) and identified ischemia on SPECT-MPI (AUC 0.759; ischemia 55.2% vs 10.4%). Angio-IMR improved discrimination (IDI 0.184; NRI 0.217), supporting a practical, less invasive pathway for CMD evaluation in ANOCA.
Impact: Provides dual-modality validation of a noninvasive, angiography-derived metric to assess microvascular dysfunction and ischemia in ANOCA, a growing clinical challenge.
Clinical Implications: Angio-IMR can be integrated into invasive angiography workflows to screen for CMD and ischemia without pressure wires or hyperemia, guiding targeted therapy and further testing in ANOCA.
Key Findings
- Angio-IMR≥25 vs wire-based IMR≥25: AUC 0.917 and 91.9% classification agreement (n=74).
- High angio-IMR associated with ischemia on SPECT-MPI (55.2% vs 10.4%; AUC 0.759).
- Angio-IMR improved discrimination for ischemia (IDI 0.184; NRI 0.217; both p<0.001).
Methodological Strengths
- Two independent validation cohorts against gold-standard wire-based IMR and against SPECT-MPI.
- Clear prespecified threshold (≥25) with robust performance metrics (AUC, IDI, NRI).
Limitations
- Modest sample sizes and vessel-level analyses may limit generalizability.
- Cross-sectional diagnostic validation; lack of longitudinal clinical outcomes.
Future Directions: Prospective outcome studies to test angio-IMR–guided therapy in ANOCA; head-to-head comparisons with invasive coronary function testing across diverse centers.
BACKGROUND: Coronary microvascular dysfunction (CMD) accounts for a significant part of angina with non-obstructive coronary artery (ANOCA). Angiography-derived index of microcirculatory resistance (angio-IMR) has been developed for the evaluation of CMD but not yet validated sufficiently in ANOCA. AIMS: To validate angio-IMR against wire-based IMR and to investigate its diagnostic performance for ischemia in ANOCA patients. METHODS: This study included two independent cohorts. The angio-IMR and wire-based IMR were measured in 74 patients (74 vessels) in the wire-based IMR validation cohort. The angio-IMR and single-photon emission computed tomography-myocardial perfusion imaging (SPECT-MPI) were successfully completed in 136 patients (408 vessels) in the SPECT-MPI validation cohort. The ischemia was defined as the myocardial perfusion defect on SPECT-MPI and a summed difference score (SDS) ≥ 2. RESULTS: In the wire-based IMR validation cohort, the angio-IMR ≥ 25 had the high diagnostic efficiency (area under the receiver-operating characteristics curve (AUC): 0.917, 95 %CI: 0.843-0.922; p < 0.001) and classification agreement (CA) (91.9 %) with the referenced wire-based IMR ≥ 25. In the SPECT-MPI validation cohort, more ischemia was observed in the high angio-IMR group (angio-IMR ≥ 25) compared to the low angio-IMR group (angio-IMR < 25) (55.2 % vs 10.4 %, p < 0.001). The angio-IMR ≥ 25 had a moderate diagnostic performance for ischemia (AUC: 0.759, 95 %CI: 0.670-0.849; p < 0.001), and it could improve the ability to discriminate ischemia in ANOAC patients (integrated discrimination improvement (IDI): 0.184; p < 0.001; net reclassification improvement (NRI): 0.217; p < 0.001). CONCLUSION: The study demonstrates that angio-IMR, validated through both wire-based IMR and SPECT-MPI, presents a promising and convenient diagnostic approach for identifying ischemia in patients with ANOCA.